Immunotherapy

Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing to fund the advancement of…

Metastatic breast cancer (MBC) remains incurable, with approximately only one-third of diagnosed women meeting the five year survival rate. Subtypes like triple-negative breast cancer (TNBC) or heavily pretreated hormone receptor-positive…